{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2015-D-1211\" and posted_year = 2023 sorted by posted_date descending", "rows": [["FDA-2015-D-1211-0368", "FDA", "FDA-2015-D-1211", "Reference 7 Van de perre p re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:33Z", null, 0, 0, "09000064859fc420"], ["FDA-2015-D-1211-0397", "FDA", "FDA-2015-D-1211", "Reference 36_FAIR_Conclusions from the For the Assessment of Individualized Risk (FAIR) group re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:55Z", null, 0, 0, "09000064859fd93c"], ["FDA-2015-D-1211-0402", "FDA", "FDA-2015-D-1211", "Reference 41_Blood safety implications of donors using HIV preexposure prophylaxis re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:59Z", null, 0, 0, "09000064859fd941"], ["FDA-2015-D-1211-0394", "FDA", "FDA-2015-D-1211", "Reference 33- O Brien - Donor screening question alternatives to men who have sex with men time deferral  Potential (1) re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:52Z", null, 0, 0, "09000064859fd865"], ["FDA-2015-D-1211-0403", "FDA", "FDA-2015-D-1211", "Reference 42_AABB_Updated Recommendations on Donor Deferral for Use of Antiretroviral Medications for HIV Prevention and Treatment re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:08:00Z", null, 0, 0, "09000064859fd942"], ["FDA-2015-D-1211-0362", "FDA", "FDA-2015-D-1211", "Reference 1 REV. Epstein_et_al-2013-Transfusion re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:29Z", null, 0, 0, "09000064859fbfcf"], ["FDA-2015-D-1211-0370", "FDA", "FDA-2015-D-1211", "Reference 9 HIV and the blood supply re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:35Z", null, 0, 0, "09000064859fc422"], ["FDA-2015-D-1211-0390", "FDA", "FDA-2015-D-1211", "Reference 29 REV. Custer - Transfusion-transmissible infection re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:50Z", null, 0, 0, "09000064859fd861"], ["FDA-2015-D-1211-0360", "FDA", "FDA-2015-D-1211", "Recommendations for Evaluating Donor Eligibility Using Individual Risk- Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2023-05-12T04:00:00Z", 2023, 5, "2023-05-12T04:00:00Z", null, "2023-05-12T12:59:32Z", "2023-10252", 0, 0, "09000064859fa444"], ["FDA-2015-D-1211-0387", "FDA", "FDA-2015-D-1211", "Reference 26 Offergeld2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:48Z", null, 0, 0, "09000064859fd85e"], ["FDA-2015-D-1211-0363", "FDA", "FDA-2015-D-1211", "Reference 2 Stramer_et_al-2013-Transfusion re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:30Z", null, 0, 0, "09000064859fbfd0"], ["FDA-2015-D-1211-0371", "FDA", "FDA-2015-D-1211", "Reference 10 Current Trends Prevention of Acquired Immune Deficiency Syndrome (AIDS)_ Report of Inter-Agency Recommendations re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:35Z", null, 0, 0, "09000064859fc423"], ["FDA-2015-D-1211-0374", "FDA", "FDA-2015-D-1211", "Reference 13 Donor-Testing-and-Risk-2012 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:38Z", null, 0, 0, "09000064859fd845"], ["FDA-2015-D-1211-0386", "FDA", "FDA-2015-D-1211", "Reference 25 REV. Custer - Blood DROPS re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:47Z", null, 0, 0, "09000064859fd85b"], ["FDA-2015-D-1211-0399", "FDA", "FDA-2015-D-1211", "Reference 38_NHS Blood and Transplant_Our Improved Donations Safety Check re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:56Z", null, 0, 0, "09000064859fd93e"], ["FDA-2015-D-1211-0405", "FDA", "FDA-2015-D-1211", "Reference 44_New Ref 44_HIV incidence in US first-time blood donors during 12-month and 3-month MSM deferral policy periods re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:08:01Z", null, 0, 0, "09000064859fd944"], ["FDA-2015-D-1211-0385", "FDA", "FDA-2015-D-1211", "Reference 24 REV. Custer2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:46Z", null, 0, 0, "09000064859fd85a"], ["FDA-2015-D-1211-0395", "FDA", "FDA-2015-D-1211", "Reference 34 Goldman.MSM Policy changes in Canada.Transfusion.2022 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:53Z", null, 0, 0, "09000064859fd866"], ["FDA-2015-D-1211-0400", "FDA", "FDA-2015-D-1211", "Reference 39_FDA_Important Information for Potential Donors of Blood and Blood Products re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:56Z", null, 0, 0, "09000064859fd93f"], ["FDA-2015-D-1211-0404", "FDA", "FDA-2015-D-1211", "Reference 43 New Reference 43_HIV antiretroviral therapy and prevention use in US blood re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:08:00Z", null, 0, 0, "09000064859fd943"], ["FDA-2015-D-1211-0379", "FDA", "FDA-2015-D-1211", "Reference 18_FDA Blood Products Advisory Committee Meeting_September 14-15 2000 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:41Z", null, 0, 0, "09000064859fd84a"], ["FDA-2015-D-1211-0384", "FDA", "FDA-2015-D-1211", "Reference 23 REV. ACBTSA re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:46Z", null, 0, 0, "09000064859fd859"], ["FDA-2015-D-1211-0392", "FDA", "FDA-2015-D-1211", "Refernce 31_HIV Risk Behavior Profiles Among Men Who Have Sex with Men Interested in Donating Blood_ADVANCE Study re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:51Z", null, 0, 0, "09000064859fd863"], ["FDA-2015-D-1211-0401", "FDA", "FDA-2015-D-1211", "Reference 40_Initiation of anti-retroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:57Z", null, 0, 0, "09000064859fd940"], ["FDA-2015-D-1211-0367", "FDA", "FDA-2015-D-1211", "Reference 6 Pubhealthrep00106-0104 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:33Z", null, 0, 0, "09000064859fbfd4"], ["FDA-2015-D-1211-0372", "FDA", "FDA-2015-D-1211", "Reference 11 Transfusion-associated_infections re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:36Z", null, 0, 0, "09000064859fd727"], ["FDA-2015-D-1211-0380", "FDA", "FDA-2015-D-1211", "Reference 19 FDA Workshop on Behavior-Based Donor Deferral in the NAT Era 2006 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:42Z", null, 0, 0, "09000064859fd84b"], ["FDA-2015-D-1211-0383", "FDA", "FDA-2015-D-1211", "Reference 22_FDA workshop on Quarantine Release Errors in Blood Establishments_September 2011 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:45Z", null, 0, 0, "09000064859fd858"], ["FDA-2015-D-1211-0393", "FDA", "FDA-2015-D-1211", "Reference 32_Caffrey_Removing MSM.Canada.CliniqueTransfusion.2022 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:52Z", null, 0, 0, "09000064859fd864"], ["FDA-2015-D-1211-0376", "FDA", "FDA-2015-D-1211", "Reference 15 MMWR_Revised Public Health Service Definition of Persons Who Should Refrain from Donating Blood and Plasma -- United States re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:39Z", null, 0, 0, "09000064859fd847"], ["FDA-2015-D-1211-0389", "FDA", "FDA-2015-D-1211", "Reference 28 Lucky2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:49Z", null, 0, 0, "09000064859fd860"], ["FDA-2015-D-1211-0398", "FDA", "FDA-2015-D-1211", "Reference 37_Patel et al_Estimating per-act HIV transmission risk re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:55Z", null, 0, 0, "09000064859fd93d"], ["FDA-2015-D-1211-0406", "FDA", "FDA-2015-D-1211", "Reference 45_New Ref 45_Modeling the Effect of an Individual-Risk Based Deferral Policy re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:08:02Z", null, 0, 0, "09000064859fd945"], ["FDA-2015-D-1211-0364", "FDA", "FDA-2015-D-1211", "Reference 3 Dubin_et_al-2013-Transfusion re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:31Z", null, 0, 0, "09000064859fbfd1"], ["FDA-2015-D-1211-0365", "FDA", "FDA-2015-D-1211", "Reference 4 Epidemiologic Notes and Reports Pneumocystis carinii Pneumonia among Persons with Hemophilia A re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:31Z", null, 0, 0, "09000064859fbfd2"], ["FDA-2015-D-1211-0366", "FDA", "FDA-2015-D-1211", "Reference 5 Epidemiologic Notes and Reports Possible Transfusion-Associated Acquired Immune Deficiency Syndrome (AIDS) -- California re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:32Z", null, 0, 0, "09000064859fbfd3"], ["FDA-2015-D-1211-0375", "FDA", "FDA-2015-D-1211", "Reference 14 Klamroth2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:38Z", null, 0, 0, "09000064859fd846"], ["FDA-2015-D-1211-0373", "FDA", "FDA-2015-D-1211", "Reference 12 Ward et al_JAMA_256_3_028 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:37Z", null, 0, 0, "09000064859fd844"], ["FDA-2015-D-1211-0361", "FDA", "FDA-2015-D-1211", "Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Other", "Guidance", "2023-05-12T04:00:00Z", 2023, 5, "2023-05-12T04:00:00Z", null, "2024-11-11T21:24:16Z", null, 1, 0, "09000064859fa827"], ["FDA-2015-D-1211-0369", "FDA", "FDA-2015-D-1211", "Reference 8 FDA Memorandum Recommendations to decrease the Risk of Tramitting AIDS fro Blood donors re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:34Z", null, 0, 0, "09000064859fc421"], ["FDA-2015-D-1211-0377", "FDA", "FDA-2015-D-1211", "Reference 16_FDA Blood Products Advisory Committee Meeting_December 11 1997 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:40Z", null, 0, 0, "09000064859fd848"], ["FDA-2015-D-1211-0396", "FDA", "FDA-2015-D-1211", "Reference 35_Advisory Committee on the Safety of Blood Tissues and Organs (SaBTO)_Donor Selection Criteria Report re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:54Z", null, 0, 0, "09000064859fd867"], ["FDA-2015-D-1211-0378", "FDA", "FDA-2015-D-1211", "Reference 17_FDA Workshop on Donor Suitability 1998 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:40Z", null, 0, 0, "09000064859fd849"], ["FDA-2015-D-1211-0382", "FDA", "FDA-2015-D-1211", "Reference 21 Quarantine-release-errors-white-paper re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:44Z", null, 0, 0, "09000064859fd84d"], ["FDA-2015-D-1211-0391", "FDA", "FDA-2015-D-1211", "Reference 30_ADVANCE Study re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:50Z", null, 0, 0, "09000064859fd862"], ["FDA-2015-D-1211-0381", "FDA", "FDA-2015-D-1211", "Reference 20 HHS Advisory Committee for blood safety and availability mtg 2010 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:43Z", null, 0, 0, "09000064859fd84c"], ["FDA-2015-D-1211-0388", "FDA", "FDA-2015-D-1211", "Reference 27 Seed2010 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry", "Supporting & Related Material", "Background Material", "2023-05-12T04:00:00Z", 2023, 5, null, null, "2023-05-12T20:07:48Z", null, 0, 0, "09000064859fd85f"], ["FDA-2015-D-1211-0274", "FDA", "FDA-2015-D-1211", "Guidance Documents Related to Coronavirus Disease 2019 (COVID\u201319)", "Notice", "General Notice", "2023-03-13T04:00:00Z", 2023, 3, "2023-03-13T04:00:00Z", null, "2023-03-13T14:09:01Z", "2023-05094", 0, 0, "090000648579b2d7"], ["FDA-2015-D-1211-0151", "FDA", "FDA-2015-D-1211", "Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2023-01-30T05:00:00Z", 2023, 1, "2023-01-30T05:00:00Z", null, "2023-02-28T14:29:29Z", "2023-01796", 0, 0, "0900006485618fef"], ["FDA-2015-D-1211-0155", "FDA", "FDA-2015-D-1211", "Reference 17_FDA Workshop on Donor Suitability 1998", "Supporting & Related Material", "Background Material", "2023-01-30T05:00:00Z", 2023, 1, null, null, "2023-01-30T14:18:43Z", null, 0, 0, "0900006485618a78"], ["FDA-2015-D-1211-0156", "FDA", "FDA-2015-D-1211", "Reference 18_FDA Blood Products Advisory Committee Meeting_September 14-15 2000", "Supporting & Related Material", "Background Material", "2023-01-30T05:00:00Z", 2023, 1, null, null, "2023-01-30T14:19:40Z", null, 0, 0, "0900006485618a79"], ["FDA-2015-D-1211-0157", "FDA", "FDA-2015-D-1211", "Reference 19 FDA Workshop on Behavior-Based Donor Deferral in the NAT Era 2006", "Supporting & Related Material", "Background Material", "2023-01-30T05:00:00Z", 2023, 1, null, null, "2023-01-30T14:20:46Z", null, 0, 0, "0900006485618a6b"], ["FDA-2015-D-1211-0158", "FDA", "FDA-2015-D-1211", "Reference 22_FDA workshop on Quarantine Release Errors in Blood Establishments_September 2011", "Supporting & Related Material", "Background Material", "2023-01-30T05:00:00Z", 2023, 1, null, null, "2023-01-30T14:21:52Z", null, 0, 0, "0900006485618a6c"], ["FDA-2015-D-1211-0152", "FDA", "FDA-2015-D-1211", "Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry; Availability", "Other", "Guidance", "2023-01-30T05:00:00Z", 2023, 1, "2023-01-30T05:00:00Z", "2023-04-01T03:59:59Z", "2025-02-05T02:00:53Z", null, 1, 0, "0900006485618a68"], ["FDA-2015-D-1211-0159", "FDA", "FDA-2015-D-1211", "New Reference 30_ADVANCE Study", "Supporting & Related Material", "Background Material", "2023-01-30T05:00:00Z", 2023, 1, null, null, "2023-01-30T14:22:43Z", null, 0, 0, "0900006485618a6d"], ["FDA-2015-D-1211-0160", "FDA", "FDA-2015-D-1211", "New Ref 32- O Brien - Donor screening question alternatives to men who have sex with men time deferral  Potential (1)", "Supporting & Related Material", "Background Material", "2023-01-30T05:00:00Z", 2023, 1, null, null, "2023-01-30T14:24:06Z", null, 0, 0, "0900006485618a6e"], ["FDA-2015-D-1211-0154", "FDA", "FDA-2015-D-1211", "Reference 16_FDA Blood Products Advisory Committee Meeting_December 11 1997", "Supporting & Related Material", "Background Material", "2023-01-30T05:00:00Z", 2023, 1, null, null, "2023-01-30T14:17:37Z", null, 0, 0, "0900006485618a77"], ["FDA-2015-D-1211-0153", "FDA", "FDA-2015-D-1211", "New Ref 15 MMWR_Revised Public Health Service Definition of Persons Who Should Refrain from Donating Blood and Plasma -- United States", "Supporting & Related Material", "Background Material", "2023-01-30T05:00:00Z", 2023, 1, null, null, "2023-01-30T14:17:49Z", null, 0, 0, "0900006485618a6a"], ["FDA-2015-D-1211-0161", "FDA", "FDA-2015-D-1211", "New Ref 37_NHS Blood and Transplant_Our Improved Donations Safety Check", "Supporting & Related Material", "Background Material", "2023-01-30T05:00:00Z", 2023, 1, null, null, "2023-01-30T14:24:58Z", null, 0, 0, "0900006485618a7c"]], "truncated": false, "filtered_table_rows_count": 59, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 and \"posted_year\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA-2015-D-1211", "p1": "2023"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023", "results": [{"value": "FDA", "label": "FDA", "count": 59, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 54, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 3, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&document_type=Notice", "selected": false}, {"value": "Other", "label": "Other", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&document_type=Other", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023", "results": [{"value": 2023, "label": 2023, "count": 59, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&_facet=comment_start_date"}, {"name": "open_for_comment", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&_facet=open_for_comment"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2015-D-1211&posted_year=2023&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 1068.4875019360334, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}